# Alnylam Pharmaceuticals, Inc. – Consensus ‘buy’ rating and 45.3% Upside Potential

- Link: https://www.directorstalkinterviews.com/alnylam-pharmaceuticals-inc.consensus-buy-rating-and-45.3-upside-potential/4121159757
- Published: 2024-06-11T14:40:58+01:00
- Author: Charlotte Edwards

**Alnylam Pharmaceuticals, Inc.** which can be found using ticker (ALNY) now have
23 market analysts covering the stock. The analyst consensus now points to a rating
of ‘buy’. The target price High/Low ranges between $400.00 and $138.00 calculating
the average target price we see $222.04. Given that the stocks previous close was
at $152.78 this would indicate that there is a potential upside of 45.3%. There 
is a 50 day moving average of $149.55 and the 200 day moving average is $166.51.
The total market capitalization for the company now stands at 19.41B. The stock 
price is currently at: $153.47 USD

 The potential market cap would be $28,213,130,531 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of -, revenue per share of $15.97 and
a -3.05% return on assets.

Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The
Company is engaged in developing therapeutics based on ribonucleic acid interference(
RNAi). Its pipeline includes five marketed products and over ten clinical programs,
including several in late-stage development, across four strategic therapeutic areas(
STArs): genetic medicines, cardio-metabolic diseases, hepatic infectious diseases,
and CNS/ocular diseases. Its RNAi-based medicines include ONPATTRO (patisiran), 
AMVUTTRA (vutrisiran), GIVLAARI (givosiran), OXLUMO (lumasiran) and Leqvio (inclisiran).
ONPATTRO is an intravenously administered RNAi therapeutic targeting transthyretin
amyloidosis. GIVLAARI is used to reduce induced liver aminolevulinic acid synthase
1 messenger RNA (mRNA), to reduce toxins associated with attacks and other disease
manifestations of acute hepatic porphyria. OXLUMO is an RNAi therapeutic targeting
hydroxyacid oxidase 1 for the treatment of primary hyperoxaluria type 1.

Share on: